1. Home
  2. PDX vs PHAT Comparison

PDX vs PHAT Comparison

Compare PDX & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PDX
  • PHAT
  • Stock Information
  • Founded
  • PDX 2019
  • PHAT 2018
  • Country
  • PDX NY
  • PHAT United States
  • Employees
  • PDX N/A
  • PHAT N/A
  • Industry
  • PDX Finance/Investors Services
  • PHAT Biotechnology: Pharmaceutical Preparations
  • Sector
  • PDX Finance
  • PHAT Health Care
  • Exchange
  • PDX Nasdaq
  • PHAT Nasdaq
  • Market Cap
  • PDX 996.5M
  • PHAT 963.9M
  • IPO Year
  • PDX N/A
  • PHAT 2019
  • Fundamental
  • Price
  • PDX $21.95
  • PHAT $13.23
  • Analyst Decision
  • PDX
  • PHAT Strong Buy
  • Analyst Count
  • PDX 0
  • PHAT 5
  • Target Price
  • PDX N/A
  • PHAT $17.60
  • AVG Volume (30 Days)
  • PDX N/A
  • PHAT 1.1M
  • Earning Date
  • PDX 01-01-0001
  • PHAT 10-30-2025
  • Dividend Yield
  • PDX 4.95%
  • PHAT N/A
  • EPS Growth
  • PDX N/A
  • PHAT N/A
  • EPS
  • PDX N/A
  • PHAT N/A
  • Revenue
  • PDX N/A
  • PHAT $147,190,000.00
  • Revenue This Year
  • PDX N/A
  • PHAT $218.38
  • Revenue Next Year
  • PDX N/A
  • PHAT $87.14
  • P/E Ratio
  • PDX N/A
  • PHAT N/A
  • Revenue Growth
  • PDX N/A
  • PHAT 460.30
  • 52 Week Low
  • PDX $13.52
  • PHAT $2.21
  • 52 Week High
  • PDX $21.05
  • PHAT $19.05
  • Technical
  • Relative Strength Index (RSI)
  • PDX 30.33
  • PHAT 53.02
  • Support Level
  • PDX $22.07
  • PHAT $13.11
  • Resistance Level
  • PDX $22.52
  • PHAT $14.22
  • Average True Range (ATR)
  • PDX 0.36
  • PHAT 0.98
  • MACD
  • PDX 0.06
  • PHAT -0.11
  • Stochastic Oscillator
  • PDX 40.68
  • PHAT 23.87

About PDX PIMCO Dynamic Income Strategy Fund of Beneficial Interest

PIMCO Dynamic Income Strategy Fund is a non-diversified, limited-term, closed-end management investment company. It seeks current income as a primary objective and capital appreciation as a secondary objective. The fund makes investments using a dynamic asset allocation plan among multiple sectors in the public and private credit markets globally, including corporate debt, mortgage-related and other asset-backed instruments, government and sovereign debt, taxable municipal bonds, and other fixed, variable, and floating-rate income-producing securities of U.S. and foreign issuers, including emerging market issuers and real estate-related investments.

About PHAT Phathom Pharmaceuticals Inc.

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Share on Social Networks: